The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: The need for more evidence

Journal of the American Academy of Dermatology

Volumn 43, Issue 4, 2000, Pages 708-711

  Kimyai Asadi, Arash ^a   Usman, Adil ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b The New York Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; INTERLEUKIN 2;

BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; HEPATITIS C; HUMAN; LIFE EXPECTANCY; LIVER TOXICITY; MELANOMA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW;

EID: 0033781125     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2000.107500     Document Type: Article

References (15)

1. Adjuvant therapy for cutaneous malignant melanoma
2. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma
3. Results of the french multicenter trial on adjuvant therapy with interferon alfa-2a in resected primary melanoma (larger than 1.5 mm)
4. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: A Southwest Oncology Group study
5. Evaluation of efficacy of adjuvant therapy with IFN-alpha 2a in melanoma patients with regional node metastases
6. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
7. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study
8. Adjuvant interferon alfa-2b treatment in resected primary stage II cutaneous melanoma
9. Postsurgical adjuvant therapy for melanoma: Evaluation of a 3-year randomized trial with recombinant interferon-α after 3 and 5 years of follow-up
10. Randomized trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
11. NCCN melanoma practice guidelines: National Comprehensive Cancer Network
12. Alternative medicine: Is it all in your mind?
13. The power of non-specific effects in healing: Implications for psychosocial and biological treatments
14. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma
15. Malignant melanoma: Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later